Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials

BACKGROUND: Relapse-free survival (RFS) has been considered a primary endpoint to assess the effects of immunotherapy in the adjuvant setting among patients with early-stage disease. However, it is not clear whether RFS is a valid surrogate endpoint for overall survival (OS) in this clinical context...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuanfang, Yuan, Shuqiang, Chen, Yingbo, Nie, Man, Li, Jibin, Chen, Guoming, Chen, Xiaojiang, Zhang, Ruopeng, Zheng, Ziqi, Wei, Chengzhi, Zhou, Zhiwei, Nie, Runcong, Wang, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483266/
https://www.ncbi.nlm.nih.gov/pubmed/37389446
http://dx.doi.org/10.1093/jnci/djad125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483266/
https://www.ncbi.nlm.nih.gov/pubmed/37389446
http://dx.doi.org/10.1093/jnci/djad125

Ejemplares similares